Related references
Note: Only part of the references are listed.Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes
Michiko Asano et al.
DIABETES OBESITY & METABOLISM (2021)
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Rajaa Nahra et al.
DIABETES CARE (2021)
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist
Victoria E. R. Parker et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes
Daniel R. Quast et al.
DIABETES CARE (2020)
Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
Michelle L. Boland et al.
NATURE METABOLISM (2020)
MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Promotes a Dose-Dependent Increase in Gastric Emptying Time
Darren Robertson et al.
DIABETES (2019)
Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite?
John I. Malone et al.
PEDIATRIC DIABETES (2019)
Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide onmajor cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics
Jennifer B. Green et al.
AMERICAN HEART JOURNAL (2018)
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study
Philip D. Ambery et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study
Preman Kumarathurai et al.
JOURNAL OF HYPERTENSION (2017)
Regulation of hepatic glucose metabolism in health and disease
Max C. Petersen et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes
Cristina B. Guzman et al.
DIABETES OBESITY & METABOLISM (2017)
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
Michael A. Nauck et al.
DIABETES CARE (2016)
Update on the treatment of type 2 diabetes mellitus
Juan Jose Marin-Penalver et al.
WORLD JOURNAL OF DIABETES (2016)
Effect of Weight Loss on Magnetic Resonance Imaging Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis
Niraj S. Patel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus
Aisling M. Lynch et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
J. van Can et al.
INTERNATIONAL JOURNAL OF OBESITY (2014)
Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Kirk M. Habegger et al.
DIABETES (2013)
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - Relationship to postprandial glycemia
Martin Lorenz et al.
REGULATORY PEPTIDES (2013)
Abdominal adiposity and liver fat content 3 and 12 months after gastric banding surgery
Madeleine L. Heath et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2009)
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)
Robert Wilcox et al.
AMERICAN HEART JOURNAL (2008)
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
JJ Meier et al.
DIABETOLOGIA (2006)
Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial
IF Douek et al.
DIABETIC MEDICINE (2005)
Type 2 diabetes: principles of pathogenesis and therapy
M Stumvoll et al.
LANCET (2005)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Share Paper
